Evidence map›Paper›PMID 42254255›Full record

ReviewAnnals of medicine and surgery (2012)2026

Translating potential into practice: the evolving landscape of neural stem cell therapeutics in clinical applications.

Shreya Singh Beniwal, Akash Rawat, Neetika Sharma, Daniela Castro Calderón, Chimuka Mwaanga, Valentina Ardila Mora, Pulkit Saini, Rafael Everton Assunção Ribeiro da Costa, Anam Sayed Mushir Ali, Abhijeet Kumar and 4 more

Abstract readReview
In one paragraph

Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shreya Singh BeniwalLady Hardinge Medical College, New Delhi, India.
Akash RawatHimalayan Institute of Medical Sciences, Swami Ram Himalayan University, Dehradun, India.
Neetika SharmaDepartment of Neurology, All India Institute of Medical Sciences (AIIMS), Bilaspur, India.
Daniela Castro CalderónUniversidad Peruana de Ciencias Aplicadas, Lima, Peru.
Chimuka MwaangaUniversity Lecturer in Medical Biochemistry, Texila American University Zambia, Lusaka, Zambia.
Valentina Ardila MoraUniversidad Nacional de Colombia, Bogotá, DC, Colombia.ORCID https://orcid.org/0009-0008-0956-3252
Pulkit SainiSri Devaraj Urs Medical College, Kolar, Karnataka, India.
Rafael Everton Assunção Ribeiro da CostaState University of Campinas, Cidade Universitária "Zeferino Vaz," Barão Geraldo, Campinas, São Paulo, Brazil.
Anam Sayed Mushir Ali⁠Indian Institute of Medical Science and Research, Jalna, India.ORCID https://orcid.org/0000-0002-8794-9803
Abhijeet KumarDepartment of General Medicine, NSMCH, Bihta, Patna, Bihar, India.
Ayush DwivediDanylo Halytsky Lviv National Medical University, Lviv oblast, Ukraine.ORCID https://orcid.org/0009-0005-1955-9116
Shubh Prashant MehtaB.J. Medical College, New Civil Hospital, Ahmedabad, Gujarat, India.
Dhruv Rakeshkumar PatelB.J. Medical College, New Civil Hospital, Ahmedabad, Gujarat, India.
Pranathi DandaMediciti Institute of Medical Sciences, Hyderabad, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neural stem cell (NSC) therapeutics have emerged as a promising approach for addressing neurological disorders due to their inherent ability to self-renew, differentiate into neural lineages, and secrete neurotrophic factors. Methods: This narrative review explores the evolving clinical landscape of NSC applications, highlighting their therapeutic potential in neurodegenerative diseases, ischemic stroke, and spinal cord injuries. Findings: Recent clinical advancements demonstrate the safety and preliminary efficacy of NSC-based therapies in conditions like Parkinson's disease and amyotrophic lateral sclerosis. NSCs' capacity to promote neuroplasticity and tissue restoration underscores their potential in reversing synaptic and neuronal damage. Despite these advancements, significant challenges remain. Ethical considerations, particularly concerning cell sourcing and patient consent, must be carefully navigated. Technical barriers, including cell delivery, survival, and long-term integration, require innovative solutions. Furthermore, safety concerns such as tumor formation and immune rejection necessitate rigorous preclinical and clinical assessments. Regulatory challenges, including the standardization of manufacturing processes and international harmonization, are essential for widespread adoption. Conclusion: Looking ahead, the integration of precision medicine, advanced biomaterials, and patient-specific-induced pluripotent stem cells offers promising approaches to enhance NSC therapeutics. Collaborative efforts between researchers, clinicians, and regulatory agencies are crucial for overcoming existing barriers and translating NSC research into clinical practice, offering new hope for patients with complex neurological conditions.

Indexed as

amyotrophic lateral sclerosisneural stem cellsneuroregenerationParkinson’s diseaseregenerative medicine

Identifiers

PMID42254255
PMCPMC13236158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.